There are 2789 resources available
LBA26 - Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16)
Presenter: Richard Cathomas
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
578MO - Phase Ib/II study of sabizabulin (VERU-111), an androgen receptor transport disruptor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent (ARTA)
Presenter: Mark Markowski
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
828MO - Exonic mutation profile of primary gastrointestinal diffuse large B-cell lymphoma
Presenter: Shan-Shan Li
Session: Mini oral session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
829MO - A gene signature to predict risk of transformation in patients with follicular lymphoma
Presenter: Ismael Fernandez-Miranda
Session: Mini oral session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
Discussion 578MO and 579MO
Presenter: Giulia Baciarello
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
Discussion 7MO, 1801MO and 1802MO
Presenter: Christian Ottensmeier
Session: Mini oral session - Basic science
Resources:
Slides
Webcast
Discussion 723MO and 724MO
Presenter: Ana Oaknin
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
Discussion LBA50, LBA51 & 1194MO
Presenter: David Gandara
Session: Mini oral session - NSCLC, metastatic
Resources:
Slides
Webcast
Discussion 828MO, 829MO and 830MO
Presenter: Andrew Davies
Session: Mini oral session - Haematological malignancies
Resources:
Slides
Webcast
Discussion 831MO and 832MO
Presenter: Ingrid Glimelius
Session: Mini oral session - Haematological malignancies
Resources:
Slides
Webcast